-
2 months ago | 
heart.bmj.com | Valentina Bracun |Adriaan A. Voors |Serge Masson |Peter Kastner
To compare patients with low, medium and high BMP10 concentrations, patients were divided into tertiles based on their BMP10 concentrations. Normally distributed variables are presented as means (SD), whereas non-normally distributed variables are presented as medians (quartiles) and categorical variables as percentages.
-
Jan 20, 2025 | 
onlinelibrary.wiley.com | Hailun Qin |Adriaan A. Voors
Introduction Chronic excessive alcohol consumption may lead to alcohol-related cardiomyopathy and is a well-established risk factor for developing heart failure (HF). However, the effects of lower doses of alcohol consumption remain controversial.
-
Nov 29, 2024 | 
heart.bmj.com | Valentina Bracun |Adriaan A. Voors |Serge Masson |Peter Kastner
Contributors DCHC: methodology, validation, formal analysis, writing—original draft, visualisation. VB: investigation, data curation, writing—review and editing. BJvE: methodology, formal analysis, validation, writing—review and editing. AAV: conceptualisation, writing—review and editing. RAdB: conceptualisation, writing—review and editing. JMtM: conceptualisation, methodology, writing—review and editing. SM: writing—review and editing. PK: methodology. CCL: writing—review and editing.
-
Nov 4, 2024 | 
onlinelibrary.wiley.com | Thong Huy Cao |Adriaan A. Voors |Leong L Ng |Slingsby OC
Leong L. Ng Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK Leicester van Geest Multi-OMICS facility, University of Leicester, Leicester, UKSearch for more papers by this author
-
Oct 28, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Oct 24, 2024 | 
onlinelibrary.wiley.com | Nicolas Girerd |Université de Lorraine |Adriaan A. Voors |Jozine ter Maaten
Invited Editorial Exploring the role of hypertonic saline in ambulatory heart failure management: One size does not fit all?
-
Sep 1, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
-
Aug 14, 2024 | 
onlinelibrary.wiley.com | Joao Ferreira |Adriaan A. Voors
Letter to the Editor Reply to ‘Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?’ João Pedro Ferreira, Corresponding Author João Pedro Ferreira UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal Corresponding author. Email: [email protected] for more papers by this authorAdriaan A. Voors, Adriaan A.
-
Mar 8, 2024 | 
nature.com | Adriaan A. Voors |Hailun Qin
AbstractAlthough sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response.
-
Sep 14, 2023 | 
nature.com | George Markousis-Mavrogenis |Ali A. Al-Mubarak |Nils Bomer |Adriaan A. Voors |Lukas Baumhove
AbstractThe immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects.
